updated 9/16/2010 2:16:22 AM ET 2010-09-16T06:16:22

SOMERSET, N.J., Sept. 15, 2010 (GLOBE NEWSWIRE) -- inVentiv Health, a leading provider of end-to-end clinical development, launch and commercialization services to the global healthcare industry, announced today that Joe Massaro, former Senior Vice President of Global Business Services at Thermo Fisher Scientific and current Managing Director at Liberty Lane Partners, LLP, has been appointed Chief Financial Officer. Massaro succeeds David Bassin, appointed CFO in 2007, who is now pursuing other opportunities.

"On behalf of our board and the rest of our management team, I am pleased to welcome Joe Massaro to inVentiv," said Blane Walter, Chief Executive Officer of inVentiv Health. "Joe has nearly two decades of world-class experience that is well matched to inVentiv's global growth trajectory. We look forward to his contributions."

"We would also like to thank David Bassin for his years of service and leadership," Walter continued. "David has helped establish inVentiv as an industry leader and his efforts have been instrumental in driving success for the company during the past decade and in creating a strong foundation for continued global growth. We appreciate his commitment to working with Joe to effect a smooth transition and we all wish him well in his future endeavors."

Massaro has over 18 years of experience as a finance executive in complex service, distribution and manufacturing organizations. He is currently a Managing Director at Liberty Lane Partners, LLP, a private investment firm which applies its unique operational and financial expertise to its portfolio companies to achieve above-market returns. Previously, Massaro served in several senior financial and operational roles at Thermo Fisher Scientific, including Senior Vice President of Global Business Services and Vice President of Corporate Finance and Accounting. Prior to Thermo Fisher, he served in various capacities in the advisory business services practice at PricewaterhouseCoopers in Boston.

About inVentiv Health

inVentiv Health, Inc. is a leading, global provider of data-driven, outsourced solutions to the pharmaceutical, life sciences and healthcare industries. inVentiv's full suite of marketing, sales, clinical development and post-approval solutions drive speed and effectiveness across all phases of the product lifecycle, leading to quicker development and superior results throughout product launch and commercialization. inVentiv's client roster consists of more than 350 leading pharmaceutical, biotech, life sciences and healthcare payer companies. For more information, visit www.inventivhealth.com .

The inVentiv Health, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4942

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com